Cargando…

Correction: Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Miscellaneous
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547853/ https://www.ncbi.nlm.nih.gov/pubmed/32816783 http://dx.doi.org/10.1136/annrheumdis-2019-216839corr1

Ejemplares similares

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
por: Landewé, Robert, et al.
Publicado: (2020)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
por: Marin, Josefina, et al.
Publicado: (2018)

Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol
por: Maksymowych, Walter P., et al.
Publicado: (2021)

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
por: van der Heijde, D., et al.
Publicado: (2017)

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2022)

Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients
por: Martín-Varillas, José Luis, et al.
Publicado: (2022)

Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2021)

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
por: Carron, Philippe, et al.
Publicado: (2016)

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
por: van der Heijde, Désirée, et al.
Publicado: (2017)

The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW
por: van der Horst-Bruinsma, Irene, et al.
Publicado: (2020)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis
por: Braun, Jürgen, et al.
Publicado: (2017)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study
por: Katsifis, Gkikas, et al.
Publicado: (2022)

Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
por: Vande Casteele, N., et al.
Publicado: (2017)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
por: Hannech, Emna, et al.
Publicado: (2021)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
por: Paul, Stéphane, et al.
Publicado: (2020)

Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study
por: Robinson, Philip C., et al.
Publicado: (2022)

(99m)Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
por: Lambert, Bieke, et al.
Publicado: (2016)

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis
por: Nozaki, Yuji, et al.
Publicado: (2021)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
por: Fleischmann, Roy, et al.
Publicado: (2017)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
por: Colombo, Elisabetta, et al.
Publicado: (2009)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
por: Blonski, Wojciech, et al.
Publicado: (2012)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015)

Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
por: Bailey, Kathryn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nfoohjo60jbpod6178i60rgvc6